SQSTM1 and hepatocellular carcinoma: This phospho-p62/SQSTM1-Nrf2 axis-dependent metabolic reprogramming is involved in the survival and chemoresistance of HCC cells and is, thus, a therapeutic target for designing anticancer drugs with improved efficacy (Table 4) [512].